RxDoctor Payments DataLook up a doctor →

Francis Buto, MD

Internal Medicine · Aiea, HINPI 1124061189

Payments from drug & device makers

$9,972in general payments, 2019–2025

Across 669 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Amarin Pharma, Inc.$886
  • Boehringer Ingelheim$828
  • AstraZeneca$779
  • plus $4K from 23 others

What the payments were for

  • Food & beverage$9,954100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,972 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$140,481
Medicare patients
442
Services billed
1,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$111,967
OzempicSemaglutide63$86,188
EliquisApixaban72$78,034
JanuviaSitagliptin Phosphate54$73,711
RybelsusSemaglutide13$29,968
FarxigaDapagliflozin Propanediol25$27,738
TradjentaLinagliptin21$26,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$25,042
Atorvastatin Calcium636$19,384
Rosuvastatin Calcium271$12,943
Breo ElliptaFluticasone/Vilanterol23$12,018
Olmesartan Medoxomil102$9,280
ByettaExenatide11$9,019
Wixela InhubFluticasone Propion/Salmeterol68$8,978
Losartan Potassium342$7,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$828$137,98396 claims
Novo NordiskOzempic, Rybelsus$1,044$116,15676 claims
PfizerEliquis$440$78,03472 claims
MerckJanuvia$253$73,71154 claims
AstraZenecaFarxiga, Byetta, Symbicort$779$39,98150 claims
GSKTrelegy Ellipta, Breo Ellipta$707$37,06043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →